Trial Profile
Australian Mepolizumab Registry for Severe Asthma
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms AMR
- 22 Apr 2021 Planned End Date changed from 30 Jun 2021 to 30 Apr 2021.
- 22 Apr 2021 Status changed from recruiting to suspended.
- 05 Mar 2020 Results (n=339) assessing the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia, published in the European Respiratory Journal